Formoterol, a highly β 2-selective agonist, increases energy expenditure and fat utilisation in men

International Journal of Obesity

Volumn 37, Issue 4, 2013, Pages 593-597

  Lee, P ^a,b,c   Day, R O ^b,c   Greenfield, J R ^a,b,c   Ho, K K Y ^a,b,c  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

beta agonist; brown adipose tissue; diet induced thermogenesis; energy expenditure; formoterol

Indexed keywords

CARBOHYDRATE; FAT; FATTY ACID; FORMOTEROL FUMARATE;

ADULT; ANOREXIA; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; DIET; ENERGY EXPENDITURE; FAT INTAKE; FAT OXIDATION; FATTY ACID BLOOD LEVEL; FEMALE; FOOD INTAKE; HEART PALPITATION; HEART RATE; HUMAN; INSOMNIA; MALE; MEAN ARTERIAL PRESSURE; OBESITY; OPEN STUDY; OUTCOME ASSESSMENT; OXIDATION; PRIORITY JOURNAL; RESTING ENERGY EXPENDITURE; SIDE EFFECT; TACHYCARDIA; THERMOGENESIS; TREMOR;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; CALORIMETRY, INDIRECT; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENERGY METABOLISM; ETHANOLAMINES; FATTY ACIDS, NONESTERIFIED; HEART RATE; HUMANS; MALE; OXIDATION-REDUCTION; THERMOGENESIS; TREATMENT OUTCOME;

EID: 84876181569     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2012.90     Document Type: Article

References (29)

1. Bray GA, Inoue S, Nishizawa Y. Hypothalamic obesity. The autonomic hypothesis and the lateral hypothalamus. Diabetologia 1981; 20(Suppl): 366-377.
2. Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK et al. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002; 297: 843-845.
3. Lee P, Zhao JT, Swarbrick MM, Gracie G, Bova R, Greenfield JR et al. High prevalence of brown adipose tissue in adult humans. J Clin Endocrinol Metab 2011; 96: 2450-2455.
4. Bjorgell P, Belfrage P. Characteristics of the lipolytic beta-adrenergic receptors in hamster adipocytes. Biochem Biophys Acta 1982; 713: 80-85.
5. Mersmann HJ. Acute metabolic effects of adrenergic agents in swine. Am J Physiol 1987; 252(1 Part 1): E85-E95.
6. Lee P, Kengne AP, Greenfield JR, Day RO, Chalmers J, Ho KK. Metabolic sequelae of beta-blocker therapy: weighing in on the obesity epidemic? Int J Obes 2011; 35: 1395-1403.
7. Schiffelers SL, Saris WH, Boomsma F, van Baak MA. beta(1)-and beta(2)-Adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men. J Clin Endocrinol Metab 2001; 86: 2191-2199.
8. Lofdahl CG, Svedmyr N. Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 1989; 44: 264-271.
9. Trazzi S, Mutti E, Frattola A, Imholz B, Parati G, Mancia G. Reproducibility of non-invasive and intra-arterial blood pressure monitoring: implications for studies on antihypertensive treatment. J Hypertens 1991; 9: 115-119.
10. Burt MG, Gibney J, Ho KK. Characterization of the metabolic phenotypes of Cushing's syndrome and growth hormone deficiency: a study of body composition and energy metabolism. Clin Endocrinol 2006; 64: 436-443.
11. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 1988; 37: 287-301.
12. O'Sullivan AJ, Kelly JJ, Hoffman DM, Freund J, Ho KK. Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab 1994; 78: 381-386.
13. Astrup A. The sympathetic nervous system as a target for intervention in obesity. Int J Obes Relat Metab Disord 1995; 19(Suppl 7): S24-S28.
14. Hoeks J, van Baak MA, Hesselink MK, Hul GB, Vidal H, Saris WH et al. Effect of beta1-and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans. Am J Physiol Endocrinol Metab 2003; 285(4): E775-E782.
15. Blaak EE, Schiffelers SL, Saris WH, Mensink M, Kooi ME. Impaired beta-adre-nergically mediated lipolysis in skeletal muscle of obese subjects. Diabetologia 2004; 47: 1462-1468.
16. Jocken JW, Roepstorff C, Goossens GH, van der Baan P, van Baak M, Saris WH et al. Hormone-sensitive lipase serine phosphorylation and glycerol exchange across skeletal muscle in lean and obese subjects: effect of beta-adrenergic stimulation. Diabetes 2008; 57: 1834-1841.
17. Jocken JW, Blaak EE, van der Kallen CJ, van Baak MA, Saris WH. Blunted beta-adrenoceptor-mediated fat oxidation in overweight subjects: a role for the hormone-sensitive lipase gene. Metabolism 2008; 57: 326-332.
18. Jocken JW, Blaak EE, Schiffelers S, Arner P, van Baak MA, Saris WH. Association of a beta-2 adrenoceptor (ADRB2) gene variant with a blunted in vivo lipolysis and fat oxidation. Int J Obes 2007; 31: 813-819.
19. Blaak EE, van Baak MA, Saris WH. Beta-adrenergically stimulated fat oxidation is diminished in middle-aged compared to young subjects. J Clin Endocrinol Metab 1999; 84: 3764-3769.
20. Blaak EE, Kemerink GJ, Pakbiers MT, Wolffenbuttel BH, Heidendal GA, Saris WH. Micro-dialysis assessment of local adipose tissue lipolysis during beta-adrenergic stimulation in upper-body-obese subjects with type II diabetes. Clin Sci 1999; 97: 421-428.
21. Blaak EE, Saris WH, Wolffenbuttel BH. Substrate utilization and thermogenic responses to beta-adrenergic stimulation in obese subjects with NIDDM. Int J Obes Relat Metab Disord 1999; 23: 411-418.
22. Kraenzlin ME, Keller U, Keller A, Thelin A, Arnaud MJ, Stauffacher W. Elevation of plasma epinephrine concentrations inhibits proteolysis and leucine oxidation in man via beta-adrenergic mechanisms. J Clin Invest 1989; 84: 388-393.
23. White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens 1999; 12(2 Part 2): 50S-55S.
24. Ryall JG, Schertzer JD, Lynch GS. Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia. J Gerontol A Biol Sci Med Sci 2007; 62: 813-823.
25. Philipson LH. beta-Agonists and metabolism. J Allergy Clin Immunol 2002; 110(6 Suppl): S313-S317.
26. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; 55(8): 650-656.
27. Brodde OE, Daul A, Michel MC. Subtype-selective modulation of human beta 1-and beta 2-adrenoceptor function by beta-adrenoceptor agonists and antagonists. Clin Physiol Biochem 1990; 8(Suppl 2): 11-17.
28. Lynch GS, Ryall JG. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008; 88(2): 729-767.
29. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 2009; 360(15): 1500-1508.